You just read:

Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy

News provided by

Audentes Therapeutics, Inc.

Sep 27, 2017, 08:00 ET